脾多肽联合化疗对乳腺癌患者T淋巴细胞亚群、生活质量及血清肿瘤标志物的影响

目的:探讨脾多肽联合化疗治疗乳腺癌患者的临床疗效。方法:选取我院于2015年2月～2019年2月期间收治的93例乳腺癌患者,根据乱数表法将患者分为研究组(n=47,脾多肽联合化疗)、对照组(n=46,常规化疗),比较两组临床疗效、T淋巴细胞亚群、生活质量、血清肿瘤标志物、不良反应。结果:研究组治疗4个周期后的临床总有效率为78.72%(37/47),显著高于对照组的56.52%(26/46)(P0.05)。研究组治疗4个周期后CD3~+、CD4~+、CD4~+/CD8~+以及情感功能、躯体功能、总体健康、精神状态评分高于对照组,CD8~+则低于对照组(P0.05)。研究组治疗4个周期后血清糖类抗原153(CA153)、肿瘤特异性生长因子(TSGF)、组织多肽特异性抗原(TPS)水平低于对照组(P0.05)。两组患者不良反应发生率比较无差异(P0.05)。结论:脾多肽联合化疗治疗乳腺癌患者的疗效显著,可有效改善其T淋巴细胞亚群、生活质量及血清肿瘤标志物水平,用药安全性较好。

Effects of Splenic Polypeptide Combined with Chemotherapy on T Lymphocyte Subsets, Quality of Life and Serum Tumor Markers in Patients with Breast Cancer

ABSTRACT Objective: To investigate the effects of splenic polypeptide combined with chemotherapy on T lymphocyte subsets, quality of life and serum tumor markers in patients with breast cancer. Methods: 93 patients with breast cancer who were admitted to our hospital from February 2015 to February 2019 were selected, and they were divided into study group (n=47, spleen polypeptide combined chemotherapy) and control group (n=46, routine chemotherapy) according to random number table method. The clinical efficacy, T lymphocyte subsets, quality of life, serum tumor markers and adverse reactions were compared between two groups. Results: The total effective rate of the study group was 78.72% (37/47) at 4 cycles after treatment, which was significantly higher than that of the control group 56.52% (26/46)(P<0.05). At 4 cycles after treatment, the levels of CD3⁺, CD4⁺, CD4⁺/CD8⁺, the scores of emotional function, physical function, general health and mental state in the study group were higher than those in the control group, while the levels of CD8⁺ in the study group was lower than that in the control group(P<0.05). The levels of serum Carbohydrate antigen 153(CA153), tumor specific growth factor (TSGF), tissue polypeptide specific antigen (TPS) in the study group were lower than those in the control group at 4 cycles after treatment(P<0.05). There was no difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: Spleen polypeptide combined with chemotherapy is effective in the treatment of breast cancer. It can effectively improve T lymphocyte subsets, quality of life and serum tumor markers. It has good safety.